GlassScriptPhysician profile
Jawwad Yusuf
NPI 1548425622
$11,136.89
in general payments reported to CMS, 2019-2025
38 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $257 · 2021: $261 · 2022: $951 · 2023: $4,654 · 2024: $2,458 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,982 · Travel and Lodging: $1,857 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,981.66 |
| Travel and Lodging | $1,856.86 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,807.09 | 2019-2025 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
| Edwards Lifesciences Corporation | $1,597.25 | 2022-2024 | Pascal, Swan-Ganz |
| Abiomed | $742.91 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $715.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $633.23 | 2022-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $605.56 | 2021-2025 | Onyx Frontier |
| Amgen INC. | $523.24 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $471.41 | 2023-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $387.10 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $357.11 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $345.32 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $319.38 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $266.56 | 2019-2025 | Avvigo Guidance System, Watchman Flx |
| Impulse Dynamics (USA) INC. | $249.07 | 2023 | Optimizer |
| Livanova USA, INC. | $237.52 | 2020-2023 | Protekduo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.83 | 2023-2025 | Jardiance |
| Shockwave Medical, INC | $222.75 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bridgebio Pharma, INC. | $158.10 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $149.38 | 2019-2023 | Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $146.33 | 2025 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $136.09 | 2022-2024 | Xarelto |
| Medtronic Vascular, INC. | $118.02 | 2019-2020 | |
| Scpharmaceuticals INC. | $110.38 | 2023-2024 | |
| Philips North America LLC | $96.27 | 2023 | |
| United Therapeutics Corporation | $86.15 | 2022 | |
| Heartflow, INC. | $64.81 | 2023-2025 | Ffrct |
| Cardiovascular Systems INC. | $58.10 | 2019-2021 | |
| Daiichi Sankyo INC. | $55.42 | 2023 | Injectafer |
| Itamar Medical INC | $52.72 | 2023-2025 | Watchpatone |
| Bard Peripheral Vascular, INC. | $42.20 | 2023 | Lutonix Drug Coated Balloon |
| Irhythm Technologies, INC. | $39.53 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Medicomp INC | $26.22 | 2023 | Telepatch Cardiac Monitor |
| Baxter Healthcare | $21.70 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| W. L. Gore & Associates, INC. | $18.40 | 2021 | |
| Intact Vascular, INC. | $16.28 | 2019 | |
| Teleflex LLC | $15.77 | 2023 | Manta |
| Cardinal Health 200 LLC | $13.51 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawwad Yusuf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.